PR Newswire Clinical TrialsOriginal article
Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
BLA FilingOpamtistomigPositive
AI Analysis
Summary
Nanjing Leads Biolabs announced Priority Review designation for its BLA application for Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody monotherapy, for the treatment of extrapulmonary neuroendocrine carcinoma. The priority review status accelerates the commercialization pathway and addresses an unmet medical need in this indication.
Outcome Details
Priority Review granted for BLA submission
Importance:7/10
Sentiment:
0.75
priority reviewBLA filingbispecific antibodyPD-L1/4-1BBneuroendocrine carcinomamonotherapyunmet need
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 10, 2026 8:53 AM